Pre-made Sirtratumab benchmark antibody ( Whole mAb ADC, anti-SLITRK6 therapeutic antibody, Anti-DFNMYP Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Sirtratumab biosimilar, Whole mAb ADC, Anti-SLITRK6 Antibody: Anti-DFNMYP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Sirtratumab vedotin is an antibody drug conjugate (ADC) that delivers a small molecule microtubule-disrupting agent, monomethyl auristatin E (MMAE), to tumor cells expressing SLITRK6.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-524-1mg	1mg	4635
GMP-Bios-ab-524-10mg	10mg	Inquiry
GMP-Bios-ab-524-100mg	100mg	Inquiry
GMP-Bios-ab-524-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Sirtratumab biosimilar, Whole mAb ADC, Anti-SLITRK6 Antibody: Anti-DFNMYP therapeutic antibody
INN Name	Sirtratumab
Target	SLITRK6
Format	Whole mAb ADC
Derivation
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2017
Year Recommended	2018
Companies	Astellas/Agensys;Seattle Genetics
Conditions Approved	na
Conditions Active	Bladder Cancer
Conditions Discontinued	na
Development Tech	na